-
ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF MICROWAVE ABLATION VS. RADIOFREQUENCY ABLATION AND SURGICAL RESECTION FOR EARLY-STAGE HEPATOCELLULAR CARCINOMA IN THE MEXICAN PUBLIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
ESTIMATING PRICE ELASTICITIES OF ALCOHOL DEMAND IN CHINA (2010-2024)
Mar 18, 2026, 21:38 PM -
DEVELOPING DIRECT EQUITY WEIGHTS FOR COST-EFFECTIVENESS ANALYSIS: RESULTS FROM A US-BASED DISCRETE CHOICE EXPERIMENT
Mar 18, 2026, 21:38 PM -
FACTORS ASSOCIATED WITH LONGITUDINAL TRAJECTORIES OF HYDROXYUREA ADHERENCE AMONG INDIVIDUALS WITH SICKLE CELL DISEASE: A GROUP-BASED TRAJECTORY MODELING STUDY
Mar 18, 2026, 21:38 PM -
THERAPEUTIC ROLE OF ALISKIREN MONOTHERAPY IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTIHYPERTENSIVE AND ANTIPROTEINURIC EFFECTS
Mar 18, 2026, 21:38 PM -
CHARACTERIZING AGE-RELATED PATTERNS IN HEALTHCARE COSTS AND UTILIZATION AMONG PEOPLE LIVING WITH ANGELMAN SYNDROME IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
DESCRIBING THE ROLE OF CAREGIVERS IN ATTR-CM: A SECONDARY ANALYSIS OF SURVEY DATA FROM GERMANY AND SPAIN
Mar 18, 2026, 21:38 PM -
INDIRECT TREATMENT COMPARISON OF TEPROTUMUMAB VS RITUXIMAB OR TOCILIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Mar 18, 2026, 21:38 PM -
PREDICTING CHRONIC KIDNEY DISEASE IN PATIENTS WITH OBESITY: A PREDICTIVE MODELING APPROACH FOR PREVENTIVE CARE
Mar 18, 2026, 21:38 PM -
COST PER CLINICAL WEIGHT-LOSS GOAL ACHIEVEMENT WITH SEMAGLUTIDE 2.4 MG VERSUS LIRAGLUTIDE 3 MG FROM A COLOMBIAN INSURER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
CAUSAL AI IN EPIDEMIOLOGY AND HEALTHCARE: CONCEPTS AND METHODOLOGIES
Mar 18, 2026, 21:38 PM -
REAL-WORLD (RW) DISEASE PROGRESSION AND HEALTHCARE RESOURCE UTILIZATION (HCRU) AMONG PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE UNITED STATES (US)
Mar 18, 2026, 21:38 PM -
ROBOTIC-ASSISTED PYELOPLASTY USING THE DA VINCI SURGICAL SYSTEMS COMPARED TO LAPAROSCOPIC OR OPEN APPROACH: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
Mar 18, 2026, 21:38 PM -
THE DIFFERENTIAL IMPACT OF FAMILY-LEVEL MULTIMORBIDITY ON FINANCIAL HARDSHIP BY INSURANCE STATUS EVIDENCE FROM MEPS 2018-2023
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS AND VALUE MATRIX IN A STRUCTURED MODEL FOR THE PROVISION OF IMMUNOBIOLOGIC THERAPIES IN DERMATOLOGY: A REAL-WORLD ANALYSIS
Mar 18, 2026, 21:38 PM -
VALIDATION OF AN ECONOMIC TOOL TO ESTIMATE THE DIRECT COSTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D) IN COLOMBIA, ECUADOR, PERU, GUATEMALA, AND EL SALVADOR, AND TO ESTIMATE THE RETURN ON INVESTMENT (ROI...
Mar 18, 2026, 21:38 PM -
MAPPING HUMAN EFFORT DISPLACEMENT IN AI-ASSISTED HEOR WORKFLOWS
Mar 18, 2026, 21:38 PM -
PATIENT EXPERIENCE AND NET PROMOTER SCORE IN A STRUCTURED DERMATOLOGICAL IMMUNOBIOLOGIC CARE MODEL: REAL-WORLD EVIDENCE TO SUPPORT VALUE-BASED HEALTHCARE
Mar 18, 2026, 21:38 PM -
THE IMPACT OF CHRONIC KIDNEY DISEASE AND ANEMIA ON THE ASSOCIATION BETWEEN FASTING PLASMA GLUCOSE AND HBA1C LEVELS
Mar 18, 2026, 21:38 PM -
A COMPARISON OF DIRECT MEDICAL COSTS IN VERTEBROPLASTY AND KYPHOPLASTY IN JAPAN AND IMPLICATIONS FOR IMPACTS ON THE BUDGET
Mar 18, 2026, 21:38 PM
